title: [Rare, but important chronic liver diseases].
abstract: The presence of steatosis and inflammatory infiltrate in liver biopsies is essential for the diagnosis of non-alcoholic steatohepatitis (NASH). These findings are similar to those with alcoholic liver disease. However, in the NASH-situation alcohol doesn't play an important role. Risk factors for the development of NASH are obesity and diabetes. Most of the patients are clinically asymptomatic. This means, that a diagnosis of NASH is a diagnosis of exclusion: Viral induced, autoimmune, metabolic and toxic liver disease have to be excluded. The disease has a benign clinical course. The risk of cirrhosis is low. So far, there is no established treatment. Preliminary reports suggest a positive effect of weight-loss and ursodeoxycholic acid. Wilson's disease, a copper storage disorder, in which biliary copper excretion is reduced, is inherited as an autosomal recessive trait. Most patients with Wilson disease become symptomatic between the ages of 6 and 15. In about 90% of patients serum ceruloplasmin levels and serum copper concentrations are reduced. Copper excreation is increased. Histologic examination of liver biopsy specimens reveals fatty infiltration, Mallory bodies and ballooned glycogen nuclei, abnormalities which are also found in alcoholic liver disease. The definitive diagnostic parameter is the quantitative determination of liver copper content (> 250 micrograms/g dryweight). Untreated Wilson disease is always fatal. Lifelong treatment with anti-copper drugs are essential, D-penicillamine being the firstline therapy. Hereditary hemochromatosis (HH) is an iron overload disease inherited as an autosomal recessive trait. The frequency of the disease is high. The first symptoms usually can be found at the age of 20-50 years. Arthralgia develops in up to 50% of the patients. Many organs are involved, most often the liver. The organ is usually enlarged, transaminases are always moderately elevated. Laboratory findings disclose a marked elevation in serum ferritin and transferrin saturation. More than 80% of HH-patients are homozygous for the C282Y-mutation in the HFE-gene. The firstline treatment of HH is phlebotomy. Treatment is lifelong. When serum ferritin drops below 50 micrograms/l, the frequency of phlebotomy should be reduced (4-12 per year). If the patient already has cirrhosis, the risk of HCC is very high.
authors.affiliation: Medizinische Klinik, Fachbereich Gastroenterologie, Städtische Kliniken Esslingen, Akademisches Lehrkrankenhaus der Universität Tübingen.
authors.forename: K P
authors.initials: KP
authors.lastname: Maier
mesh_terms: D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002570:Ceruloplasmin / Q000032:analysis; D002614:Chelating Agents / Q000627:therapeutic use; D002648:Child; D002908:Chronic Disease; D003300:Copper / Q000097:blood; D048909:Diabetes Complications; D003937:Diagnosis, Differential; D005234:Fatty Liver / Q000175:diagnosis / Q000209:etiology; D005293:Ferritins / Q000097:blood; D006432:Hemochromatosis / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D006527:Hepatolenticular Degeneration / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000150:complications; D008875:Middle Aged; D009154:Mutation; D009765:Obesity / Q000150:complications; D010396:Penicillamine / Q000627:therapeutic use; D018962:Phlebotomy; D012307:Risk Factors; D014168:Transferrin / Q000032:analysis
chemical_list: D002614:Chelating Agents; D014168:Transferrin; D003300:Copper; D005293:Ferritins; D002570:Ceruloplasmin; D010396:Penicillamine